The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 16th 2025
Aficamten, a cardiac myosin inhibitor, gains FDA approval, offering hope for improved cardiovascular health in patients with obstructive hypertrophic cardiomyopathy.
Antifungal Receives FDA Orphan Drug Designation for Invasive Candidiasis
November 3rd 2014Astellas today announced that the FDA has granted orphan drug designation to isavuconazole for the treatment of invasive candidiasis, one of the most frequent invasive fungal infections detected in critically ill patients and a common cause of bloodstream infections.
Read More
CHEST Foundation's Lung Cancer Awareness Campaign Now Underway
November 3rd 2014The CHEST Foundation recently launched its Lung Cancer Care: A Team Approach campaign as part of National Lung Cancer Awareness Month. The campaign aims to raise awareness about low treatment rates and the importance of medical specialists working together to provide optimal lung cancer care.
Read More
Report: Performance Measures Should Include Patient Actions
November 3rd 2014The actions - or inaction - of patients should be considered in programs designed to improve care and patient outcomes, according to a report released today by the American College of Cardiology, American Heart Association, American Association of Cardiovascular and Pulmonary Rehabilitation, American Academy of Family Physicians and the American Nurses Association in collaboration with other professional organizations.
Read More
City of Houston and Novo Nordisk partner to lead fight against urban diabetes epidemic
November 3rd 2014The City of Houston and Novo Nordisk today announced an innovative partnership to fight the urban diabetes epidemic. Houston is the third city globally and the first in the United States to join the Cities Changing Diabetes programme, which was initiated earlier in 2014 by Novo Nordisk. The first two cities are Mexico City and Copenhagen.
Read More
Bristol-Myers Squibb Company and Galecto Biotech AB today announced that the companies, together with the Galecto shareholders, have entered into an agreement that provides Bristol-Myers Squibb the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead asset TD139, a novel inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.
Read More
Atrial Fibrillation Drug Approval Endorsed by FDA Committee
October 31st 2014The FDA's Cardiovascular and Renal Drugs Advisory Committee has recommended the approval of edoxaban (Savaysa) for treating patients with nonvalvular atrial fibrillation, a type of arrhythmia that can potentially cause a stroke.
Read More